Provided by Tiger Fintech (Singapore) Pte. Ltd.

IceCure Medical Ltd.

1.42
+0.04002.90%
Post-market: 1.440.0200+1.41%19:47 EDT
Volume:172.13K
Turnover:242.30K
Market Cap:80.33M
PE:-4.96
High:1.45
Open:1.39
Low:1.38
Close:1.38
Loading ...

Icecure Medical: Strong Growth and Regulatory Momentum Support Buy Rating

TIPRANKS
·
28 Nov 2024

IceCure Medical Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
27 Nov 2024

IceCure Medical Sees Strong Growth Amid ProSense® Adoption

TIPRANKS
·
27 Nov 2024

IceCure Medical price target raised to $4.60 from $4.16 at Brookline

TIPRANKS
·
27 Nov 2024

IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates

Zacks
·
26 Nov 2024

IceCure Medical GAAP EPS of $0.22 , revenue of $2.41M

seekingalpha
·
26 Nov 2024

IceCure Medical’s Promising Growth and FDA Anticipation

TIPRANKS
·
26 Nov 2024

IceCure Medical reports 36% sales growth in first nine months of 2024

TIPRANKS
·
26 Nov 2024

Press Release: IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense(R) Cryoablation

Dow Jones
·
26 Nov 2024

IceCure Medical’s Cryoablation Innovation Gains Momentum

TIPRANKS
·
25 Nov 2024

BRIEF-Icecure's Next-Generation Multiprobe Cryoablation Technology Issued Notice Of Allowance From Japan's Patent Office

Reuters
·
25 Nov 2024

IceCure Medical receives Notice of Allowance from Japan’s Patent Office

TIPRANKS
·
25 Nov 2024

Icecure Medical Ltd: Terumo Corporation Plans to File for Regulatory Approval of Prosense for Breast Cancer in 2025

THOMSON REUTERS
·
25 Nov 2024

Icecure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance From Japan's Patent Office

THOMSON REUTERS
·
25 Nov 2024

IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office

PR Newswire
·
25 Nov 2024

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

PR Newswire
·
20 Nov 2024